Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - pantoprazole sodium sesquihydrate -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - pantoprazole sodium sesquihydrate -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - gabapentin, quantity: 300 mg - capsule - excipient ingredients: lactose monohydrate; maize starch; purified talc; gelatin; purified water; sodium lauryl sulfate; titanium dioxide; iron oxide yellow - gabapentin is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs. gabapentin is indicated for the treatment of neuropathic pain.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - gabapentin, quantity: 100 mg - capsule - excipient ingredients: lactose monohydrate; maize starch; purified talc; gelatin; purified water; sodium lauryl sulfate; titanium dioxide - gabapentin is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs. gabapentin is indicated for the treatment of neuropathic pain.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - amoxicillin trihydrate, quantity: 574 mg (equivalent: amoxicillin, qty 500 mg); potassium clavulanate, quantity: 149 mg (equivalent: amoxicillin, qty 500 mg; equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; purified talc; povidone; triethyl citrate; hypromellose; titanium dioxide; ethylcellulose - short-term treatment of bacterial infection at the following sites when caused by amoxycillin/clavulanic acid sensitive, beta-lactamase producing organisms. skin and skin structure infections. urinary tract infections (uncomplicated and complicated). upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxycillin/clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the microbiological section, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

apotex corp. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide nasal solution, 0.06% is indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for adults and children age 5 years and older. ipratropium bromide nasal solution, 0.06% does not relieve nasal congestion or sneezing associated with the common cold or seasonal allergic rhinitis. the safety and effectiveness of the use of ipratropium bromide nasal solution, 0.06% beyond four days in patients with the common cold or beyond three weeks in patients with seasonal allergic rhinitis has not been established. ipratropium bromide nasal solution, 0.06% is contraindicated in patients with a history of hypersensitivity to atropine or its derivatives, or to any of the other ingredients. ipratropium bromide nasal solution, 0.06% nasal spray (ip" ra troe' pee um broe' mide) rx only read complete instructions carefully before using. in order to ensure proper dosing, do not attempt to change the size of the spray opening. ipratropium bromide nasal solution, 0.06% is indicated for the symptomatic relief of rhinorrhea (runny nose) associated with the common cold or seasonal allergic rhinitis for adults and children age 5 years and older. ipratropium bromide nasal solution, 0.06% does not relieve nasal congestion or sneezing associated with the common cold or seasonal allergic rhinitis. do not use ipratropium bromide nasal solution, 0.06% for longer than four days for a common cold or three weeks for seasonal allergic rhinitis unless instructed by your physician. read complete instructions carefully and use only as directed. to use - remove the clear plastic dust cap and the green safety clip from the nasal spray pump (figure 1). the safety clip prevents the accidental discharge of the spray in your pocket or purse.           figure 1                                                                               figure 1 - the nasal spray pump must be primed before ipratropium bromide nasal solution, 0.06% is used for the first time. to prime the pump, hold the bottle with your thumb at the base and your index and middle fingers on the white shoulder area. make sure the bottle points upright and away from your eyes. press your thumb firmly and quickly against the bottle seven times (figure 2). the pump is now primed and can be used. your pump should not have to be reprimed unless you have not used the medication for more than 24 hours; repriming the pump will only require two sprays. if you have not used your nasal spray for more than seven days, repriming the pump will require seven sprays.  figure 2                                         figure 2 - before using  ipratropium bromide nasal solution, 0.06%, blow your nose gently to clear your nostrils if necessary. - close one nostril by gently placing your finger against the side of your nose, tilt your head slightly forward and, keeping the bottle upright, insert the nasal tip into the other nostril (figure 3). point the tip toward the back and outer side of the nose.  figure 3                                                                                 figure 3 - press firmly and quickly upwards with the thumb at the base while holding the white shoulder portion of the pump between your index and middle fingers. following each spray, sniff deeply and breathe out through your mouth. - after spraying the nostril and removing the unit, tilt your head backwards for a few seconds to let the spray spread over the back of the nose. - repeat steps 4 through 6 in the same nostril. - repeat steps 4 through 7 in the other nostril (i.e., two sprays per nostril). - replace the clear plastic dust cap and safety clip. - at some time before the medication is completely used up, you should consult your physician or pharmacist to determine whether a refill is needed. you should not take extra doses or stop using ipratropium bromide nasal solution, 0.06% without consulting your physician. to clean if the nasal tip becomes clogged, remove the clear plastic dust cap and safety clip. hold the nasal tip under running, warm tap water (figure 4) for about a minute. dry the nasal tip, reprime the nasal spray pump (step 2 above), and replace the plastic dust cap and safety clip.                                                             figure 4                                                       caution     ipratropium bromide nasal solution, 0.06% is intended to relieve your rhinorrhea (runny nose) with regular use. it is therefore important that you use ipratropium bromide nasal solution, 0.06% as prescribed by your physician. for most patients, some improvement in runny nose is apparent following the first dose of treatment with ipratropium bromide nasal solution, 0.06%. do not use ipratropium bromide nasal solution, 0.06% for longer than four days for your cold or three weeks for seasonal allergic rhinitis unless instructed by your physician. do not spray ipratropium bromide nasal solution, 0.06% in your eyes. should this occur, immediately flush your eye with cool tap water for several minutes. if you accidentally spray ipratropium bromide nasal solution, 0.06% in your eyes, you may experience a temporary blurring of vision, visual halos or colored images in association with red eyes from conjunctival and corneal congestion, development or worsening of narrow-angle glaucoma, pupil dilation, or acute eye pain/discomfort, and increased sensitivity to light, which may last a few hours. should acute eye pain or blurred vision occur, contact your doctor. should you experience excessive nasal dryness or episodes of nasal bleeding, contact your doctor. if you have glaucoma or difficulty urinating due to an enlargement of the prostate, be sure to tell your physician prior to using ipratropium bromide nasal solution, 0.06%. if you are pregnant or you are breast feeding your baby, be sure to tell your physician prior to using ipratropium bromide nasal solution, 0.06%. address medical inquiries to apotex corp: (800) 706-5575. storage store tightly closed at 20°to  25°c (68° to  77°f) [see usp controlled room temperature]. avoid freezing. keep out of reach of children. manufactured by:                              manufactured for: apotex inc.                                      apotex corp. toronto, ontario                               weston, fl canada m9l 1t9                              33326 may 2014

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

apotex europe b.v. - voriconazole - film coated tablet - 50 milligram - voriconazole - antimycotics for systemic use, triazole derivatives - voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows: treatment of invasive aspergillosis. treatment of candidemia in non-neutropenic patients. treatment of fluconazole-resistant serious invasive candida infections (including c. krusei). treatment of serious fungal infections caused by scedosporium spp. and fusarium spp. voriconazole apotex should be administered primarily to patients with progressive, possibly life-threatening infections. prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

apotex europe b.v. - voriconazole - film coated tablet - 200 milligram - voriconazole - antimycotics for systemic use, triazole derivatives - voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows: treatment of invasive aspergillosis. treatment of candidemia in non-neutropenic patients. treatment of fluconazole-resistant serious invasive candida infections (including c. krusei). treatment of serious fungal infections caused by scedosporium spp. and fusarium spp. voriconazole apotex should be administered primarily to patients with progressive, possibly life-threatening infections. prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - voriconazole -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - voriconazole -